Vitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagy

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPIRES, Daniela A.
dc.contributor.authorBRANDAO-RANGEL, Maysa A. R.
dc.contributor.authorSILVA-REIS, Anamei
dc.contributor.authorOLIMPIO, Fabiana R. S.
dc.contributor.authorAIMBIRE, Flavio
dc.contributor.authorOLIVEIRA, Carlos R.
dc.contributor.authorMATEUS-SILVA, Jose R.
dc.contributor.authorZAMARIOLI, Lucas S.
dc.contributor.authorBACHI, Andre L. L.
dc.contributor.authorBELLA, Yanesko F.
dc.contributor.authorSANTOS, Juliana M. B.
dc.contributor.authorBINCOLETTO, Claudia
dc.contributor.authorJR, Antonio Herbert Lancha
dc.contributor.authorVIEIRA, Rodolfo P.
dc.date.accessioned2024-04-05T19:42:23Z
dc.date.available2024-04-05T19:42:23Z
dc.date.issued2024
dc.description.abstractBackground: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the overproduction of white blood cells, leading to symptoms such as fatigue, infections, and other complications. CML patients must take measures to prevent infections to mitigate the exacerbation of cancer cell proliferation and comorbidities. Methods: This study investigated whether vitamin C can suppress the hyperinflammatory activation of K-562 cells induced by lipopolysaccharide (LPS) and whether purinergic signaling (ATP and P2X7 receptor) and autophagy play a role in it. Two different doses of vitamin C (5 mu g/mL and 10 mu g/mL) were employed, along with the lysosome inhibitor chloroquine (CQ; 100 mu M), administered 2 h prior to LPS stimulation (10 ng/mL) for a duration of 22 h in K-562 cells (3 x 10(5) cells/mL/well). Results: Both doses of vitamin C reduced the release of interleukin-6 (IL-6) (5 mu g/mL, p < 0.01 and 10 <mu>g/mL, p < 0.01) and tumor necrosis factor (TNF) (5 <mu>g/mL, p < 0.01 and 10 <mu>g/mL, p < 0.01) induced by LPS. Furthermore, in LPS + CQ-stimulated cells, vitamin C at a concentration of 10 <mu>g/mL inhibited the expression of LC3-II (p < 0.05). Conversely, both doses of vitamin C led to the release of the anti-inflammatory cytokine interleukin-10 (IL-10) (5 <mu>g/mL, p < 0.01 and 10 <mu>g/mL, p < 0.01), while only the 10 <mu>g/mL dose of vitamin C induced the release of Klotho (10 mu g/mL, p < 0.01). In addition, both doses of vitamin C reduced the accumulation of ATP (5 <mu>g/mL, p < 0.01 and 10 <mu>g/mL, p < 0.01) and decreased the expression of the P2X7 receptor at the mRNA level. Conclusions: Vitamin C inhibits the hyperinflammatory state induced by LPS in K-562 cells, primarily by inhibiting the ATP accumulation, P2X7 receptor expression, and autophagy signaling.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexScopus
dc.description.indexDimensions
dc.description.indexWoS
dc.description.sponsorshipSao Paulo Research Foundation (FAPESP)
dc.identifier.citationNUTRIENTS, v.16, n.3, article ID 383, 14p, 2024
dc.identifier.doi10.3390/nu16030383
dc.identifier.eissn2072-6643
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/59255
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofNutrients
dc.rightsopenAccesseng
dc.rights.holderCopyright MDPIeng
dc.subjectascorbic acideng
dc.subjectvitamin Ceng
dc.subjectpurinergic signalingeng
dc.subjectleukemiaeng
dc.subjectautophagyeng
dc.subjectinflammationeng
dc.subject.othertumor-necrosis-factoreng
dc.subject.otherexpressioneng
dc.subject.otherimatinibeng
dc.subject.otherdeatheng
dc.subject.otherreceptorseng
dc.subject.othersurvivaleng
dc.subject.otheril-10eng
dc.subject.otheralphaeng
dc.subject.othermouseeng
dc.subject.wosNutrition & Dieteticseng
dc.titleVitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagyeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalPIRES, Daniela A.:Univ Brasil, Postgrad Program Bioengn, Rua Carolina Fonseca 235, BR-08230030 Sao Paulo, SP, Brazil
hcfmusp.author.externalBRANDAO-RANGEL, Maysa A. R.:Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human Movement & Rehabil, Ave Ana Costa 95, BR-11060001 Santos, SP, Brazil
hcfmusp.author.externalSILVA-REIS, Anamei:Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human Movement & Rehabil, Ave Ana Costa 95, BR-11060001 Santos, SP, Brazil
hcfmusp.author.externalOLIMPIO, Fabiana R. S.:Fed Univ Sao Paulo UNIFESP, Dept Med, Postgrad Program Translat Med, Rua Pedro Toledo 720, BR-04039002 Sao Paulo, SP, Brazil
hcfmusp.author.externalAIMBIRE, Flavio:Fed Univ Sao Paulo UNIFESP, Dept Med, Postgrad Program Translat Med, Rua Pedro Toledo 720, BR-04039002 Sao Paulo, SP, Brazil
hcfmusp.author.externalOLIVEIRA, Carlos R.:Gap Biotech Lab Biotechnol & Bioinformat, Rua Comendador Remo Cesaroni 223, BR-12243020 Sao Jose Dos Campos, SP, Brazil
hcfmusp.author.externalMATEUS-SILVA, Jose R.:Gap Biotech Lab Biotechnol & Bioinformat, Rua Comendador Remo Cesaroni 223, BR-12243020 Sao Jose Dos Campos, SP, Brazil
hcfmusp.author.externalZAMARIOLI, Lucas S.:Fed Univ Sao Paulo UNIFESP, Dept Pharmacol, Rua Tres Maio 100, BR-04044020 Sao Paulo, SP, Brazil
hcfmusp.author.externalBACHI, Andre L. L.:Univ Santo Amaro, Postgrad Program Hlth Sci, Rua Prof Eneas Siqueira Neto 340, BR-04829300 Sao Paulo, SP, Brazil
hcfmusp.author.externalBELLA, Yanesko F.:Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human Movement & Rehabil, Ave Ana Costa 95, BR-11060001 Santos, SP, Brazil
hcfmusp.author.externalSANTOS, Juliana M. B.:Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human Movement & Rehabil, Ave Ana Costa 95, BR-11060001 Santos, SP, Brazil
hcfmusp.author.externalBINCOLETTO, Claudia:Fed Univ Sao Paulo UNIFESP, Dept Pharmacol, Rua Tres Maio 100, BR-04044020 Sao Paulo, SP, Brazil
hcfmusp.author.externalVIEIRA, Rodolfo P.:Univ Brasil, Postgrad Program Bioengn, Rua Carolina Fonseca 235, BR-08230030 Sao Paulo, SP, Brazil; Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human Movement & Rehabil, Ave Ana Costa 95, BR-11060001 Santos, SP, Brazil; Gap Biotech Lab Biotechnol & Bioinformat, Rua Comendador Remo Cesaroni 223, BR-12243020 Sao Jose Dos Campos, SP, Brazil; Evangelical Univ Goias Unievangel, Postgrad Program Human Movement & Rehabil & Pharma, Ave Universitaria Km 3,5, BR-75083515 Anapolis, GO, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcANTONIO HERBERT LANCHA JUNIOR
hcfmusp.description.articlenumber383
hcfmusp.description.issue3
hcfmusp.description.volume16
hcfmusp.origemWOS
hcfmusp.origem.dimensionspub.1168389052
hcfmusp.origem.pubmed38337668
hcfmusp.origem.scopus2-s2.0-85184710837
hcfmusp.origem.wosWOS:001161185100001
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAgathocleous M, 2017, NATURE, V549, P476, DOI 10.1038/nature23876eng
hcfmusp.relation.referenceAlberca-Custódio RW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00237eng
hcfmusp.relation.referenceAldapt MB, 2023, ONCOLOGY-BASEL, DOI 10.1159/000534266eng
hcfmusp.relation.referenceAlmeida-Oliveira A R, 2019, Exerc Immunol Rev, V25, P50eng
hcfmusp.relation.referenceALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994eng
hcfmusp.relation.referenceAneja RK, 2011, MINERVA ANESTESIOL, V77, P986eng
hcfmusp.relation.referenceBalkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628eng
hcfmusp.relation.referenceBarbosa CMV, 2006, EUR J PHARMACOL, V542, P37, DOI 10.1016/j.ejphar.2006.06.004eng
hcfmusp.relation.referenceBella YF, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2023.114263eng
hcfmusp.relation.referenceBellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660eng
hcfmusp.relation.referenceBestach Y, 2019, LEUKEMIA RES, V86, DOI 10.1016/j.leukres.2019.106221eng
hcfmusp.relation.referenceCimmino L, 2017, CELL, V170, P1079, DOI 10.1016/j.cell.2017.07.032eng
hcfmusp.relation.referenceCojbasic I, 2023, MEDICINA-LITHUANIA, V59, DOI 10.3390/medicina59091564eng
hcfmusp.relation.referenceCouper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771eng
hcfmusp.relation.referenceCrowley LC, 2011, AM J HEMATOL, V86, P38, DOI 10.1002/ajh.21914eng
hcfmusp.relation.referenceDonadieu J, 2005, HAEMATOLOGICA, V90, P45eng
hcfmusp.relation.referenceDrill M, 2021, PURINERG SIGNAL, V17, P215, DOI 10.1007/s11302-021-09776-9eng
hcfmusp.relation.referenceDrullion C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.111eng
hcfmusp.relation.referenceFerrari D, 2000, FEBS LETT, V486, P217, DOI 10.1016/S0014-5793(00)02306-1eng
hcfmusp.relation.referenceFitch BA, 2022, BLOOD ADV, V6, P854, DOI 10.1182/bloodadvances.2021005522eng
hcfmusp.relation.referenceFoster MN, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7070092eng
hcfmusp.relation.referenceGarcia M, 2019, EUR J IMMUNOL, V49, P928, DOI 10.1002/eji.201847657eng
hcfmusp.relation.referenceGillberg L, 2018, SEMIN CANCER BIOL, V51, P59, DOI 10.1016/j.semcancer.2017.11.001eng
hcfmusp.relation.referenceSilva LMG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152890eng
hcfmusp.relation.referenceHolbrook Jonathan, 2019, F1000Res, V8, DOI 10.12688/f1000research.17023.1eng
hcfmusp.relation.referenceHuang XL, 2012, CANCER-AM CANCER SOC, V118, P3123, DOI 10.1002/cncr.26679eng
hcfmusp.relation.referenceIdzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085eng
hcfmusp.relation.referenceIwase S, 2019, AM J EMERG MED, V37, P260, DOI 10.1016/j.ajem.2018.05.040eng
hcfmusp.relation.referenceRazaul Karim M, 2017, BIOCHIMIE, V142, P51, DOI 10.1016/j.biochi.2017.08.004eng
hcfmusp.relation.referenceLarrouyet-Sarto ML, 2020, PURINERG SIGNAL, V16, P561, DOI 10.1007/s11302-020-09746-7eng
hcfmusp.relation.referenceLi Meng-Qi, 2015, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V23, P583, DOI 10.7534/j.issn.1009-2137.2015.02.056eng
hcfmusp.relation.referenceLiu X, 2017, LEUKEMIA, V31, P2376, DOI 10.1038/leu.2017.108eng
hcfmusp.relation.referenceLiu YB, 2023, DIAB MET SYND CLIN R, V17, DOI 10.1016/j.dsx.2023.102854eng
hcfmusp.relation.referenceMackenzie B, 2016, MED SCI SPORT EXER, V48, P1459, DOI 10.1249/MSS.0000000000000927eng
hcfmusp.relation.referenceFranco DM, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011811.pub2eng
hcfmusp.relation.referencePavlovsky C, 2023, J HEMATOL ONCOL, V16, DOI 10.1186/s13045-023-01440-6eng
hcfmusp.relation.referencePortugal CC, 2021, FREE RADICAL BIO MED, V163, P43, DOI 10.1016/j.freeradbiomed.2020.11.039eng
hcfmusp.relation.referencePrud'homme GJ, 2022, FRONT AGING-LAUSANNE, V3, DOI 10.3389/fragi.2022.931331eng
hcfmusp.relation.referenceRinaldi I, 2023, J BLOOD MED, V14, P261, DOI [10.2147/JBM.S382090, 10.2147/JBM.S382090Journalof]eng
hcfmusp.relation.referenceRothe K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030461eng
hcfmusp.relation.referenceSachdeva A, 2020, CANCERS, V12, DOI 10.3390/cancers12061665eng
hcfmusp.relation.referenceSáez PJ, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah7107eng
hcfmusp.relation.referenceSanchez-Correa B, 2013, CYTOKINE, V61, P885, DOI 10.1016/j.cyto.2012.12.023eng
hcfmusp.relation.referenceSchmid S, 2015, LUNG CANCER, V90, P516, DOI 10.1016/j.lungcan.2015.10.005eng
hcfmusp.relation.referenceSharifzadeh S., 2023, Cardiovasc. Hematol. Agents Med. Chem, V21, P67, DOI [10.2174/1871525720666220819123639, DOI 10.2174/1871525720666220819123639]eng
hcfmusp.relation.referenceShen N, 2019, ONCOTARGETS THER, V12, P2355, DOI 10.2147/OTT.S197535eng
hcfmusp.relation.referenceShieh CH, 2014, GLIA, V62, P592, DOI 10.1002/glia.22628eng
hcfmusp.relation.referenceSingh P, 2021, MED ONCOL, V38, DOI 10.1007/s12032-021-01462-5eng
hcfmusp.relation.referenceSun LR, 2022, DISCOV MED, V33, P93eng
hcfmusp.relation.referenceTarumoto T, 2004, EXP HEMATOL, V32, P375, DOI 10.1016/j.exphem.2004.01.007eng
hcfmusp.relation.referenceThompson DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030659eng
hcfmusp.relation.referenceWang L, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1152-zeng
hcfmusp.relation.referenceWang XS, 2014, CLIN CANCER RES, V20, P1366, DOI 10.1158/1078-0432.CCR-13-2442eng
hcfmusp.relation.referenceWillig JB, 2020, PURINERG SIGNAL, V16, P29, DOI 10.1007/s11302-019-09686-xeng
hcfmusp.relation.referenceYan YL, 2017, MOL MED REP, V15, P1777, DOI 10.3892/mmr.2017.6172eng
hcfmusp.relation.referenceYao X, 2014, PHARMACOL THERAPEUT, V141, P125, DOI 10.1016/j.pharmthera.2013.09.004eng
hcfmusp.relation.referenceYu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65eng
hcfmusp.relation.referenceZhang LH, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.860526eng
hcfmusp.relation.referenceZou D, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-1094-zeng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationebbe3834-2ed1-41e9-8c9e-c1bfa4766169
relation.isAuthorOfPublication.latestForDiscoveryebbe3834-2ed1-41e9-8c9e-c1bfa4766169
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - LIM/26